Campbell Corey L, Snell Trey K, Bennett Susi, Wyckoff John H, Heaslip Darragh, Flatt Jordan, Harris Emma K, Hartman Daniel A, Lian Elena, Bird Brian H, Stenglein Mark D, Bowen Richard A, Kading Rebekah C
Department of Microbiology, Immunology, and Pathology, Center for Vector-Borne Infectious Diseases, Colorado State University, Fort Collins, Colorado.
BioMARC, Infectious Diseases Research Center, Colorado State University, Fort Collins, Colorado.
Transbound Emerg Dis. 2022 Sep;69(5):2621-2633. doi: 10.1111/tbed.14415. Epub 2022 Jan 5.
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen with significant human and veterinary health consequences that periodically emerges in epizootics. RVFV causes fetal loss and death in ruminants and in humans can lead to liver and renal disease, delayed-onset encephalitis, retinitis, and in some cases severe haemorrhagic fever. A live attenuated vaccine candidate (DDVax), was developed by the deletion of the virulence factors NSs and NSm from a clinical isolate, ZH501, and has proven safe and immunogenic in rodents, pregnant sheep and non-human primates. Deletion of NSm also severely restricted mosquito midgut infection and inhibited vector-borne transmission. To demonstrate environmental safety, this study investigated the replication, dissemination and transmission efficiency of DDVax in mosquitoes following oral exposure compared to RVFV strains MP-12 and ZH501. Infection and dissemination profiles were also measured in mosquitoes 7 days after they fed on goats inoculated with DDvax or MP-12. We hypothesized that DDVax would infect mosquitoes at significantly lower rates than other RVFV strains and, due to lack of NSm, be transmission incompetent. Exposure of Ae. aegypti and Cx. tarsalis to 8 log plaque forming units (PFU)/ml DDVax by artificial bloodmeal resulted in significantly reduced DDVax infection rates in mosquito bodies compared to controls. Plaque assays indicated negligible transmission of infectious DDVax in Cx. tarsalis saliva (1/140 sampled) and none in Ae. aegypti saliva (0/120). Serum from goats inoculated with DDVax or MP-12 did not harbour detectable infectious virus by plaque assay at 1, 2 or 3 days post-inoculation. Infectious virus was, however, recovered from Aedes and Culex bodies that fed on goats vaccinated with MP-12 (13.8% and 4.6%, respectively), but strikingly, DDvax-positive mosquito bodies were greatly reduced (4%, and 0%, respectively). Furthermore, DDVax did not disseminate to legs/wings in any of the goat-fed mosquitoes. Collectively, these results are consistent with a beneficial environmental safety profile.
裂谷热病毒(RVFV)是一种由蚊子传播的病原体,对人类和动物健康具有重大影响,会周期性地引发动物流行病。RVFV可导致反刍动物胎儿死亡,并在人类中引发肝脏和肾脏疾病、迟发性脑炎、视网膜炎,在某些情况下还会导致严重的出血热。一种减毒活疫苗候选株(DDVax)是通过从临床分离株ZH501中缺失毒力因子NSs和NSm而开发的,已在啮齿动物、怀孕绵羊和非人类灵长类动物中证明是安全且具有免疫原性的。缺失NSm也严重限制了蚊子中肠感染并抑制了媒介传播。为了证明其环境安全性,本研究调查了与RVFV株MP - 12和ZH501相比,口服暴露后DDVax在蚊子中的复制、传播和传播效率。还在以接种DDVax或MP - 12的山羊为食7天后的蚊子中测量了感染和传播情况。我们假设DDVax感染蚊子的速率将显著低于其他RVFV株,并且由于缺乏NSm,其不具备传播能力。通过人工血餐使埃及伊蚊和致倦库蚊暴露于8 log蚀斑形成单位(PFU)/ml的DDVax,与对照组相比,蚊子体内的DDVax感染率显著降低。蚀斑试验表明,在致倦库蚊唾液中可忽略不计地传播传染性DDVax(1/140采样),而在埃及伊蚊唾液中未检测到(0/120)。接种DDVax或MP - 12的山羊血清在接种后1、2或3天通过蚀斑试验未检测到可检测到的传染性病毒。然而,从以接种MP - 12的山羊为食的伊蚊和库蚊体内回收了传染性病毒(分别为13.8%和4.6%),但引人注目的是,DDVax阳性蚊子体内的数量大幅减少(分别为4%和0%)。此外,在任何以山羊为食的蚊子中,DDVax都没有传播到腿部/翅膀。总体而言,这些结果与有益的环境安全状况一致。